Virtanen Tuomas
Department of Clinical Microbiology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
Front Allergy. 2022 Jan 27;2:824736. doi: 10.3389/falgy.2021.824736. eCollection 2021.
A major part of important mammalian respiratory allergens belongs to the lipocalin family of proteins. By this time, 19 respiratory mammalian lipocalin allergens have been registered in the WHO/IUIS Allergen Nomenclature Database. Originally, lipocalins, small extracellular proteins (molecular mass ca. 20 kDa), were characterized as transport proteins but they are currently known to exert a variety of biological functions. The three-dimensional structure of lipocalins is well-preserved, and lipocalin allergens can exhibit high amino acid identities, in several cases more than 50%. Lipocalins contain an internal ligand-binding site where they can harbor small principally hydrophobic molecules. Another characteristic feature is their capacity to bind to specific cell-surface receptors. In all, the physicochemical properties of lipocalin allergens do not offer any straightforward explanations for their allergenicity. Allergic sensitization begins at epithelial barriers where diverse insults through pattern recognition receptors awaken innate immunity. This front-line response is manifested by epithelial barrier-associated cytokines which together with other components of immunity can initiate the sensitization process. In the following, the crucial factor in allergic sensitization is interleukin (IL)-4 which is needed for stabilizing and promoting the type 2 immune response. The source for IL-4 has been searched widely. Candidates for it may be non-professional antigen-presenting cells, such as basophils or mast cells, as well as CD4+ T cells. The synthesis of IL-4 by CD4+ T cells requires T cell receptor engagement, i.e., the recognition of allergen peptides, which also provides the specificity for sensitization. Lipocalin and innate immunity-associated cell-surface receptors are implicated in facilitating the access of lipocalin allergens into the immune system. However, the significance of this for allergic sensitization is unclear, as the recognition by these receptors has been found to produce conflicting results. As to potential adjuvants associated with mammalian lipocalin allergens, the hydrophobic ligands transported by lipocalins have not been reported to enhance sensitization while it is justified to suppose that lipopolysaccharide plays a role in it. Taken together, type 2 immunity to lipocalin allergens appears to be a harmful immune response resulting from a combination of signals involving both the innate and adaptive immunities.
重要的哺乳动物呼吸道变应原的主要部分属于脂质运载蛋白家族。截至目前,已有19种哺乳动物呼吸道脂质运载蛋白变应原在世卫组织/国际免疫学会变应原命名数据库中登记。最初,脂质运载蛋白作为一种细胞外小分子蛋白(分子量约20 kDa),被认为是运输蛋白,但目前已知其具有多种生物学功能。脂质运载蛋白的三维结构保存完好,脂质运载蛋白变应原在某些情况下可表现出较高的氨基酸同一性,超过50%。脂质运载蛋白含有一个内部配体结合位点,可容纳主要为疏水性的小分子。另一个特征是它们与特定细胞表面受体结合的能力。总体而言,脂质运载蛋白变应原的物理化学性质并不能直接解释其致敏性。变应性致敏始于上皮屏障,通过模式识别受体的各种刺激激活固有免疫。这种一线反应表现为上皮屏障相关细胞因子,它们与免疫的其他成分一起可启动致敏过程。接下来,变应性致敏的关键因素是白细胞介素(IL)-4,它是稳定和促进2型免疫反应所必需的。人们广泛寻找IL-4的来源。其候选来源可能是非专职抗原呈递细胞,如嗜碱性粒细胞或肥大细胞,以及CD4+T细胞。CD4+T细胞合成IL-4需要T细胞受体参与,即识别变应原肽段,这也为致敏提供了特异性。脂质运载蛋白和与固有免疫相关的细胞表面受体与促进脂质运载蛋白变应原进入免疫系统有关。然而,这对变应性致敏的意义尚不清楚,因为已发现这些受体的识别产生了相互矛盾的结果。至于与哺乳动物脂质运载蛋白变应原相关的潜在佐剂,脂质运载蛋白运输的疏水性配体尚未被报道可增强致敏作用,而有理由认为脂多糖在其中起作用。综上所述,对脂质运载蛋白变应原的2型免疫似乎是一种由固有免疫和适应性免疫信号组合导致的有害免疫反应。